ArticleMolecular cell2024
Inactive Parp2 causes Tp53-dependent lethal anemia by blocking replication-associated nick ligation in erythroblasts.
Abstract read
In one paragraph
Article in Molecular cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial.Journal of pharmacokinetics and pharmacodynamics · 2026Trial
- A prospective study of serum folate levels in patients with solid tumors treated with olaparib.The oncologist · 2025Trial
- Replication stress in cancer: origins, consequences and therapeutic opportunities.Nature reviews. Cancer · 2026Review
- Programmed Clonal Expansion Associated with V(D)J Recombination Drives an ATM-Dependent Vulnerability Underlying Preferential Lymphocyte Depletion and Myeloid Bias Following DNA Damage.bioRxiv : the preprint server for biology · 2026Article
- LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor Combinations.Molecular cancer therapeutics · 2026Article
- Review
- NADCell death & disease · 2025Article
- Poly(ADP-ribose)polymerase 2 is zinc-dependent enzyme and nucleosome reorganizer.Cellular and molecular life sciences : CMLS · 2025Article
- DNA repair and the contribution to chemotherapy resistance.Genome medicine · 2025Review
- Joining of DNA breaks- interplay between DNA ligases and poly (ADP-ribose) polymerases.DNA repair · 2025Review
- Thirty Years of BRCA1: Mechanistic Insights and Their Impact on Mutation Carriers.Cancer discovery · 2025Review
- 'Where is my gap': mechanisms underpinning PARP inhibitor sensitivity in cancer.Biochemical Society transactions · 2025Review
- XRCC1 mediates PARP1- and PAR-dependent recruitment of PARP2 to DNA damage sites.Nucleic acids research · 2025Article
- Review
- Review
Corrections and comments
- Update of
Authors and funding
16 authors.
Xiaohui LinInstitute for Cancer Genetics, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA.
Dipika GuptaNew York University School of Medicine, New York, NY 10016, USA.
Alina VaitsiankovaGenome Damage and Stability Centre, University of Sussex, Brighton BN1 9RQ, UK.
Seema Khattri BhandariCancer Research Facility, Departments of Internal Medicine and Molecular Genetics & Microbiology, University of New Mexico Comprehensive Cancer Center, University of New Mexico Health Sciences Center, 915 Camino de Salud, 1 University of New Mexico, Albuquerque, NM 87131, USA.
Kay Sze Karina LeungColumbia College, Columbia University, New York, NY 10027, USA.
Demis MenolfiInstitute for Cancer Genetics, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA.
Brian J LeeInstitute for Cancer Genetics, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA.
Helen R RussellCenter for Pediatric Neurological Disease Research, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Steven GershikInstitute for Cancer Genetics, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA.
Xiaoyu HuangInstitute for Cancer Genetics, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA.
Wei GuInstitute for Cancer Genetics, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA; Department of Pathology & Cell Biology, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA.
Peter J McKinnonCenter for Pediatric Neurological Disease Research, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Françoise DantzerPoly(ADP-ribosyl)ation and Genome Integrity, Strasbourg drug discovery and development Institute (IMS), UMR7242, Centre Nationale de la Recherche Scientifique/Université de Strasbourg, Institut de Recherche de l'Ecole de Biotechnologie de Strasbourg, 300 bld. S. Brant, CS10413, 67412 Illkirch, France.
Eli RothenbergNew York University School of Medicine, New York, NY 10016, USA.
Alan E TomkinsonCancer Research Facility, Departments of Internal Medicine and Molecular Genetics & Microbiology, University of New Mexico Comprehensive Cancer Center, University of New Mexico Health Sciences Center, 915 Camino de Salud, 1 University of New Mexico, Albuquerque, NM 87131, USA.
Shan ZhaInstitute for Cancer Genetics, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA; Department of Pathology & Cell Biology, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA; Department of Pediatrics, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA; Department of Immunology & Microbiology, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA. Electronic address: sz2296@cumc.columbia.edu.
Funding
Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Shondra Michelle Miller · 1985 to 2026
$166.9MTumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3MThe Role of CTIP in Lymphocyte Development and LymphomagenesisP01CA174653 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GAUTIER, JEAN · 2014 to 2024
$17.6MStructural determinants of Pol theta functionP01CA247773 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DALE A RAMSDEN · 2020 to 2026
$15.2MATM and DNA Damage in the Nervous SystemR01NS037956 · NINDS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI MCKINNON, PETER J · 1998 to 2022
$7.6MThe role of ATM in the suppression of lymphoid malignancyR01CA158073 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Shan Zha · 2011 to 2026
$5.7MROLES OF DNA LIGASE I IN MAMMALIAN DNA METABOLISMR01GM057479 · NIGMS · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI TOMKINSON, ALAN E · 2000 to 2017
$3.7MThe role of HPF1 in radiation and genotoxic cancer therapyR01CA293675 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Shan Zha · 2024 to 2026
$3.0MThe non-catalytic function of PARP2 in DNA repair and cancer therapyR01CA271595 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Shan Zha · 2022 to 2026
$2.9MThe role of DNA-PKcs in DNA repair, lymphocyte development, RNA metabolism and tumor suppressionR01CA275184 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Shan Zha · 2022 to 2026
$2.7MGenome Stability in Glia & DiseaseR01NS123081 · NINDS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI PETER J MCKINNON · 2022 to 2026
$2.3MDNA-PKCS Phosphorylation in DNA Repair and Chromosomal TranslocationsR01CA184187 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ZHA, SHAN · 2015 to 2019
$1.8MNCI NIH HHS P01 CA174653NCI NIH HHS P01 CA247773NCI NIH HHS P30 CA013696NCI NIH HHS P30 CA021765NCI NIH HHS R01 CA158073NCI NIH HHS R01 CA184187NCI NIH HHS R01 CA226852NCI NIH HHS R01 CA271595NCI NIH HHS R01 CA275184NCI NIH HHS R01 CA276837NCI NIH HHS R01 CA293675NIGMS NIH HHS R01 GM057479NINDS NIH HHS R01 NS037956NINDS NIH HHS R01 NS123081NINDS NIH HHS R56 NS037956
Abstract
Poly (ADP-ribose) polymerase (PARP) 1 and 2 enzymatic inhibitors (PARPi) are promising cancer treatments. But recently, their use has been hindered by unexplained severe anemia and treatment-related leukemia. In addition to enzymatic inhibition, PARPi also trap PARP1 and 2 at DNA lesions. Here we report that, unlike Parp2
Indexed as
AnemiaCheckpoint Kinase 2DNA ReplicationErythroblastsPoly(ADP-ribose) PolymerasesTumor Suppressor Protein p53AnimalsDNA DamageDNA Ligase ATPErythropoiesisFemaleHumansMiceMice, Inbred C57BLMice, KnockoutPoly (ADP-Ribose) Polymerase-1Checkpoint Kinase 2Chek2 protein, mouseDNA Ligase ATPParp1 protein, mouseParp2 protein, mousePoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesTrp53 protein, mouseTumor Suppressor Protein p535′p-nicksanemiaerythropoiesishematological toxicityLig1PARP2PARP inhibitionPARP inhibitor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.